Protection from the toxicity of diisopropylfluorophosphate by adeno-associated virus expressing acetylcholinesterase

Bin Li, Ellen G. Duysen, Larisa Y Poluektova, L. Charles Murrin, Oksana Lockridge

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Organophosphorus esters (OP) are highly toxic chemicals used as pesticides and nerve agents. Their acute toxicity is attributed to inhibition of acetylcholinesterase (AChE, EC 3.1.1.7) in nerve synapses. Our goal was to find a new therapeutic for protection against OP toxicity. We used a gene therapy vector, adeno-associated virus serotype 2 (AAV-2), to deliver murine AChE to AChE-/- mice that have no endogenous AChE activity. The vector encoded the most abundant form of AChE: exons 2, 3, 4, and 6. Two-day old animals, with an immature immune system, were injected. AChE delivered intravenously was expressed up to 5 months in plasma, liver, heart, and lung, at 5-15% of the level in untreated wild-type mice. A few mice formed antibodies, but antibodies did not block AChE activity. The plasma AChE was a mixture of dimers and tetramers. AChE delivered intramuscularly had 40-fold higher activity levels than in wild-type muscle. None of the AChE was collagen-tailed. No retrograde transport through the motor neurons to the central nervous system was detected. AChE delivered intrastriatally assembled into tetramers. In brain, the AAV-2 vector transduced neurons, but not astrocytes and microglia. Vector-treated AChE-/- mice lived longer than saline-treated controls. AChE-/- mice were protected from diisopropylfluorophosphate-induced respiratory failure when the vector was delivered intravenously, but not intrastriatally. Since vector-treated animals had no AChE activity in diaphragm muscle, protection from respiratory failure came from AChE in other tissues. We conclude that AChE scavenged OP and in this way protected the activity of butyrylcholinesterase (BChE, EC 3.1.1.8) in motor endplates.

Original languageEnglish (US)
Pages (from-to)152-165
Number of pages14
JournalToxicology and Applied Pharmacology
Volume214
Issue number2
DOIs
StatePublished - Jul 15 2006

Fingerprint

Isoflurophate
Dependovirus
Acetylcholinesterase
Viruses
Toxicity
Esters
Respiratory Insufficiency
Neurons
Muscle
Motor Endplate
Animals
Butyrylcholinesterase
Muscles
Antibodies
Poisons
Cholinesterases
Plasmas
Microglia
Motor Neurons
Gene therapy

Keywords

  • AAV-2
  • Acetylcholinesterase knockout mouse
  • DFP
  • Organophosphate

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Protection from the toxicity of diisopropylfluorophosphate by adeno-associated virus expressing acetylcholinesterase. / Li, Bin; Duysen, Ellen G.; Poluektova, Larisa Y; Murrin, L. Charles; Lockridge, Oksana.

In: Toxicology and Applied Pharmacology, Vol. 214, No. 2, 15.07.2006, p. 152-165.

Research output: Contribution to journalArticle

@article{ba3ed2b816a245b487836d6f71310b93,
title = "Protection from the toxicity of diisopropylfluorophosphate by adeno-associated virus expressing acetylcholinesterase",
abstract = "Organophosphorus esters (OP) are highly toxic chemicals used as pesticides and nerve agents. Their acute toxicity is attributed to inhibition of acetylcholinesterase (AChE, EC 3.1.1.7) in nerve synapses. Our goal was to find a new therapeutic for protection against OP toxicity. We used a gene therapy vector, adeno-associated virus serotype 2 (AAV-2), to deliver murine AChE to AChE-/- mice that have no endogenous AChE activity. The vector encoded the most abundant form of AChE: exons 2, 3, 4, and 6. Two-day old animals, with an immature immune system, were injected. AChE delivered intravenously was expressed up to 5 months in plasma, liver, heart, and lung, at 5-15{\%} of the level in untreated wild-type mice. A few mice formed antibodies, but antibodies did not block AChE activity. The plasma AChE was a mixture of dimers and tetramers. AChE delivered intramuscularly had 40-fold higher activity levels than in wild-type muscle. None of the AChE was collagen-tailed. No retrograde transport through the motor neurons to the central nervous system was detected. AChE delivered intrastriatally assembled into tetramers. In brain, the AAV-2 vector transduced neurons, but not astrocytes and microglia. Vector-treated AChE-/- mice lived longer than saline-treated controls. AChE-/- mice were protected from diisopropylfluorophosphate-induced respiratory failure when the vector was delivered intravenously, but not intrastriatally. Since vector-treated animals had no AChE activity in diaphragm muscle, protection from respiratory failure came from AChE in other tissues. We conclude that AChE scavenged OP and in this way protected the activity of butyrylcholinesterase (BChE, EC 3.1.1.8) in motor endplates.",
keywords = "AAV-2, Acetylcholinesterase knockout mouse, DFP, Organophosphate",
author = "Bin Li and Duysen, {Ellen G.} and Poluektova, {Larisa Y} and Murrin, {L. Charles} and Oksana Lockridge",
year = "2006",
month = "7",
day = "15",
doi = "10.1016/j.taap.2005.12.008",
language = "English (US)",
volume = "214",
pages = "152--165",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Protection from the toxicity of diisopropylfluorophosphate by adeno-associated virus expressing acetylcholinesterase

AU - Li, Bin

AU - Duysen, Ellen G.

AU - Poluektova, Larisa Y

AU - Murrin, L. Charles

AU - Lockridge, Oksana

PY - 2006/7/15

Y1 - 2006/7/15

N2 - Organophosphorus esters (OP) are highly toxic chemicals used as pesticides and nerve agents. Their acute toxicity is attributed to inhibition of acetylcholinesterase (AChE, EC 3.1.1.7) in nerve synapses. Our goal was to find a new therapeutic for protection against OP toxicity. We used a gene therapy vector, adeno-associated virus serotype 2 (AAV-2), to deliver murine AChE to AChE-/- mice that have no endogenous AChE activity. The vector encoded the most abundant form of AChE: exons 2, 3, 4, and 6. Two-day old animals, with an immature immune system, were injected. AChE delivered intravenously was expressed up to 5 months in plasma, liver, heart, and lung, at 5-15% of the level in untreated wild-type mice. A few mice formed antibodies, but antibodies did not block AChE activity. The plasma AChE was a mixture of dimers and tetramers. AChE delivered intramuscularly had 40-fold higher activity levels than in wild-type muscle. None of the AChE was collagen-tailed. No retrograde transport through the motor neurons to the central nervous system was detected. AChE delivered intrastriatally assembled into tetramers. In brain, the AAV-2 vector transduced neurons, but not astrocytes and microglia. Vector-treated AChE-/- mice lived longer than saline-treated controls. AChE-/- mice were protected from diisopropylfluorophosphate-induced respiratory failure when the vector was delivered intravenously, but not intrastriatally. Since vector-treated animals had no AChE activity in diaphragm muscle, protection from respiratory failure came from AChE in other tissues. We conclude that AChE scavenged OP and in this way protected the activity of butyrylcholinesterase (BChE, EC 3.1.1.8) in motor endplates.

AB - Organophosphorus esters (OP) are highly toxic chemicals used as pesticides and nerve agents. Their acute toxicity is attributed to inhibition of acetylcholinesterase (AChE, EC 3.1.1.7) in nerve synapses. Our goal was to find a new therapeutic for protection against OP toxicity. We used a gene therapy vector, adeno-associated virus serotype 2 (AAV-2), to deliver murine AChE to AChE-/- mice that have no endogenous AChE activity. The vector encoded the most abundant form of AChE: exons 2, 3, 4, and 6. Two-day old animals, with an immature immune system, were injected. AChE delivered intravenously was expressed up to 5 months in plasma, liver, heart, and lung, at 5-15% of the level in untreated wild-type mice. A few mice formed antibodies, but antibodies did not block AChE activity. The plasma AChE was a mixture of dimers and tetramers. AChE delivered intramuscularly had 40-fold higher activity levels than in wild-type muscle. None of the AChE was collagen-tailed. No retrograde transport through the motor neurons to the central nervous system was detected. AChE delivered intrastriatally assembled into tetramers. In brain, the AAV-2 vector transduced neurons, but not astrocytes and microglia. Vector-treated AChE-/- mice lived longer than saline-treated controls. AChE-/- mice were protected from diisopropylfluorophosphate-induced respiratory failure when the vector was delivered intravenously, but not intrastriatally. Since vector-treated animals had no AChE activity in diaphragm muscle, protection from respiratory failure came from AChE in other tissues. We conclude that AChE scavenged OP and in this way protected the activity of butyrylcholinesterase (BChE, EC 3.1.1.8) in motor endplates.

KW - AAV-2

KW - Acetylcholinesterase knockout mouse

KW - DFP

KW - Organophosphate

UR - http://www.scopus.com/inward/record.url?scp=33745698143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745698143&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2005.12.008

DO - 10.1016/j.taap.2005.12.008

M3 - Article

C2 - 16443250

AN - SCOPUS:33745698143

VL - 214

SP - 152

EP - 165

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 2

ER -